Organization
City of Hope Comprehensive Cancer Center
76 abstracts
Abstract
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Daiichi Sankyo Inc., Rutgers Cancer Institue of New Jersey, Highlands Oncology, Washington University School of Medicine,
Abstract
Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.Org: Stephenson Cancer Center, The Tisch Cancer Institute, Mayo Clinic Cancer Center Scottsdale, The University of Arizona Cancer Center, City of Hope Comprehensive Cancer Center,
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, Boston Children's Hospital, Boston Children's Hospital and Dana-Farber Cancer Institute, St. Jude Children's Research Hospital,
Abstract
A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.Org: Mayo Clinic, Northwestern University, UCSF Helen Diller Family Comprehensive Cancer Center, University of Iowa, City of Hope National Medical Center,
Abstract
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).Org: City of Hope Comprehensive Cancer Center, Roche (China) Holding Ltd., Asan Medical Center, Genentech, Roche Products Ltd.,
Abstract
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.Org: City of Hope Comprehensive Cancer Center, CanSino Biologics, Flagstaff, Yale University School of Medicine, CTI BioPharma,
Abstract
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.Org: Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust and University of Manchester, University of Pittsburgh Medical Center (UPMC), Duke Cancer Institute,
Abstract
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,
Abstract
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.Org: University of Kansas Medical Center, Mayo Clinic, Mayo Clinic Cancer Center, Washington University in St. Louis, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Abstract
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).Org: University of Wisconsin Carbone Cancer Center, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, University of Wisconsin,
Abstract
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,
Abstract
Geriatric assessment-directed supportive care intervention (GAIN-S)-implementation via telehealth in a lower-resourced community.Org: City of Hope National Medical Center, Duarte, CA, CanSino Biologics, City of Hope National Comprehensive Cancer Center, City of Hope Comprehensive Cancer Center,
Abstract
Quality of life for older patients with metastatic cancer in Brazil: A telehealth-based geriatric assessment and supportive care intervention (GAIN-S).Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), City of Hope Comprehensive Cancer Center, University of Oklahoma Health Sciences Center, Massachusetts General Hospital, National Institute of Medical Sciences and Nutrition Salvador Zubirán,
Abstract
A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.Org: City of Hope Comprehensive Cancer Center, Translational Genomics Research Institute (TGen North), Cedars-Sinai Medical Center,
Abstract
The positive impact of Medicaid expansion on melanoma stage at presentation.Org: City of Hope Comprehensive Cancer Center, City of Hope Medical Center, City of Hope National Comprehensive Cancer Center, City of Hope Cancer Center, City of Hope National Medical Center,
Abstract
Accelerated epigenetic aging and risk of chemotoxicity in older adults with early breast cancer.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Safety of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients (pts) with biliary tract cancer with peritoneal metastases.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, CanSino Biologics,
Abstract
Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Hadassah Medical Center, City of Hope Comprehensive Cancer Center, AbbVie Inc., North Chicago, IL, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
First-in-human autologous CAR-T for metastatic breast cancers to target growth factor receptor MUC1*.Org: Minerva Biotechnologies, City of Hope Comprehensive Cancer Center, Cedars-Sinai Medical Center, University of Washington and Fred Hutchinson Cancer Research Centre, City of Hope National Medical Center,
Abstract
Characterization of cancer clinical trials in the community setting.Org: Flatiron Health, San Francisco, CA, New York Oncology Hematology PC, Nykode Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA,
Abstract
Multicenter analysis of high-dose chemotherapy (HDCT) regimens for the treatment of patients (pts) with recurrent germ cell tumors (GCTs).Org: City of Hope Comprehensive Cancer Center, UCLA Medical Center, UC Davis Comprehensive Cancer Center, Department of Medical Oncology and Therapeutics Research, University of California, Davis Comprehensive Cancer Center,
Abstract
Improving goal concordant care clinician workshops: Do patients benefit?Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, City of Hope National Comprehensive Cancer Center,
Abstract
Practice patterns in prostate cancer therapy among healthcare professionals: Comparison with expert recommendations from an online tool.Org: Clinical Care Options, LLC, City of Hope Comprehensive Cancer Center, University of California, San Diego Health, Division of Hematology & Oncology, University of Washington & Fred Hutchinson Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine,
Abstract
A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, Washington University School of Medicine in St Louis, St. Louis, MO, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).Org: START San Antonio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Mayo Clinic Cancer Center, Beth Israel Deaconess Medical Center, START Mountain Region,
Abstract
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Sarcoma Oncology Center, City of Hope Comprehensive Cancer Center, UCLA David Geffen School of Medicine,
Abstract
Interim analysis of clinical data and reasons for initiating relugolix on a cohort of US patients: The OPTYX study.Org: University Hospitals Seidman Cancer Center and Case Western Reserve University, University of California, San Diego Health, Northwestern University Feinberg School of Medicine, Department of Urology, Chicago, IL, Chesapeake Urology, Sumitomo Pharma America,
Abstract
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.Org: Huntsman Cancer Institute at the University of Utah, SWOG Statistics and Data Management Center, Seattle, WA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, University of Kentucky, Lexington, KY,
Abstract
Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).Org: Dana-Farber Cancer Institute, Harvard Medical School, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Mayo Clinic Florida,
Abstract
Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.Org: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, Beth Israel Deaconess Medical Center, Boston, MA,
Abstract
RBM10 mutation as a potential negative prognostic/predictive biomarker to therapy in non-small-cell lung cancer.Org: Department of Medical Oncology and Therapeutics Research, City of Hope National Cancer Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center,
Abstract
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, University of California at Los Angeles, Massachusetts General Hospital, University of Iowa Hospitals & Clinics,
Abstract
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).Org: City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope Beckman Research Institute, USC Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.Org: Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, UPMC Hillman Cancer Center, Abramson Cancer Center, Karmanos Cancer Institute,
Abstract
Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).Org: The Translational Genomics Research Institute (TGen), City of Hope Comprehensive Cancer Center, Centro de Cancer de Brasilia, Grupo Oncoclinicas, Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan,
Abstract
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.Org: Memorial Sloan Kettering Cancer Center, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, City of Hope Comprehensive Cancer Center, University of California Los Angeles Translational Oncology Research,
Abstract
UGT1A1 *28/*28 genotype and risk of toxicity and disease progression in breast cancer patients treated with sacituzumab govitecan-hziy.Org: City of Hope Comprehensive Cancer Center,
Abstract
Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.Org: City of Hope Comprehensive Cancer Center, SWOG Statistics and Data Management Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Yale School of Medicine, Yale University,
Abstract
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.Org: Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, City of Hope Beckman Research Institute, Cytoimmune Therapeutics,
Abstract
The effect of megestrol acetate +/- pterostilbene in endometrial cancer: A prospective, randomized, window-of-opportunity clinical trial.Org: City of Hope National Comprehensive Cancer Center, City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope Comprehensive Medical Center,
Abstract
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.Org: City of Hope Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center, The Sarah Cannon Research Institute, Knight Cancer Institute, Cedars-Sinai Cancer Center,
Abstract
Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.Org: START Midwest, Grand Rapids, MI, City of Hope Comprehensive Cancer Center, Stephenson Cancer Center University of Oklahoma/Sarah Cannon Research Institute, Stephenson Cancer Center (Oklahoma City, OK), University of North Carolina Chapel Hill School of Medicine,
Abstract
Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.Org: Wilmot Cancer Institute, University of Rochester Medical Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, City of Hope Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center,
Abstract
Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.Org: City of Hope National Medical Center, City of Hope Medical Group, City of Hope Cancer Center, City of Hope Comprehensive Cancer Center, City of Hope National Comprehensive Cancer Center,
Abstract
Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).Org: Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH,
Abstract
Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications.Org: Stanford Cancer Institute, Harvard Medical School, University of California San Francisco School of Medicine, Harvard University, Tulane University School of Medicine,
Abstract
Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, City of Hope Comprehensive Cancer Center, Centro de Cancer de Brasilia, Instituto Unity de Ensino e Pesquisa, Grupo Oncoclinicas,
Abstract
Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC).Org: City of Hope Comprehensive Cancer Center, Quantitative Medicine and Systems Biology Division, Translational Genomics Research Institute (TGen North), Integrated Cancer Genomics Division, Yale University School of Medicine,
Abstract
Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.Org: Janssen Research & Development, Sarah Cannon Research Institute/Tennessee Oncology, City of Hope Comprehensive Cancer Center,
Abstract
Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).Org: University of California Davis Comprehensive Cancer Center, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Oregon Health & Science University, Knight Cancer Institute,
Abstract
Impact of synchronous (sync) vs metachronous (meta) metastasis at the presentation on survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs).Org: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, UTC Therapeutics, Hunstman Cancer Institute at the University of Utah, City of Hope Comprehensive Cancer Center,
Abstract
Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).Org: Alliance Statistics and Data Management Center, Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center at Basking Ridge New Jersey, Dana-Farber Cancer Institute,
Abstract
HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).Org: Thermo Fisher Scientific, University of Texas MD Anderson Cancer Center, Johns Hopkins Hospital, City of Hope Comprehensive Cancer Center, CHRISTUS Health,
Abstract
Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.Org: Keck School of Medicine of the University of Southern California, Norris Comprehensive Cancer Center, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, USC/Norris Comprehensive Cancer Center,
Abstract
A first-in-human, open-label, dose escalation and expansion study of orally administered NX-019 in patients with advanced EGFR mutant cancer.Org: NEXT Oncology - Virginia Cancer Specialists, Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Yonsei Cancer Center, Yonsei University Health System,
Abstract
A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.Org: Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Huntsman Cancer Institute at the University of Utah, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center,
Abstract
HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.Org: Thompson Cancer Survival Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, City of Hope Comprehensive Cancer Center, Earle A Chiles Research Institute, Cedars-Sinai Cancer,
Abstract
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).Org: University of California Davis Comprehensive Cancer Center, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Scalable new model of genomic care delivery: Assessing psychological outcomes.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, City of Hope National Comprehensive Cancer Center,
Abstract
Healthcare utilization among individuals diagnosed with Lynch syndrome through a universal germline genetic testing program.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center,
Abstract
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.Org: Columbia University Irving Medical Center, New York, NY, USA, Columbia University - Mailman School of Public Health, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.Org: City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope National Comprehensive Cancer Center,
Abstract
Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.Org: City of Hope Comprehensive Cancer Center, Sarcoma Oncology Research Center, Santa Monica, CA, Aveni Foundation, Sarcoma Oncology Center,
Abstract
Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Santa Monica, CA, City of Hope Comprehensive Cancer Center, Duarte, CA, Aveni Foundation,
Abstract
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.Org: Columbia University Irving Medical Center, New York, NY, USA, Columbia University - Mailman School of Public Health, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, City of Hope Comprehensive Cancer Center, Washington University School of Medicine in St Louis,
Abstract
Patient characteristics associated with psychosocial distress about end-of-life.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
The association of sociodemographic variables with smoking prevalence in patients enrolled on clinical trials.Org: City of Hope National Comprehensive Cancer Center, Duarte, CA, CanSino Biologics, SWOG Statistics and Data Management Center, Seattle, WA, Seattle Gummy Company,
Abstract
New insights on oncologist use of genomic testing.Org: Research Advocacy Network/Komen AIS, Irvina, CA, CBWhite, City of Hope Comprehensive Cancer Center, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
Abstract
Factors associated with response to neoadjuvant chemotherapy and immune checkpoint inhibition in triple-negative breast cancer.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, Cedars-Sinai Cancer Center, Los Angeles Medical Center,
Abstract
Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Santa Monica, CA, Dornsife College of Letters, University of Southern California, Los Angeles, CA, University of California Los Angeles,
Abstract
Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).Org: Yonsei University College of Medicine, Seoul, Korea, Republic of (South), Taipei Medical University Hospital, Taipei City, Taiwan, City of Hope Comprehensive Cancer Center,
Abstract
Immune checkpoint inhibitor effects on male reproduction.Org: Harbor-UCLA Medical Center, Torrance, CanSino Biologics, The Lundquist Institute, City of Hope Comprehensive Cancer Center,
Abstract
Falls and hospitalization during chemotherapy in older women with early breast cancer.Org: City of Hope National Medical Center, Duarte, CA, University of Nebraska Medical Center, Omaha NE, Neurocentria,
Abstract
Evaluation of the prevalence of MET and protein tyrosine kinase 7 expression in non-small cell lung cancer to evaluate overlap of ADC antigens.Org: AbbVie Inc., North Chicago, IL, University of Colorado Denver Department of Radiation Oncology, University Hospital Birmingham NHS Foundation Trust, City of Hope Comprehensive Cancer Center, Shanghai Lung Cancer Center,
Abstract
Learning what matters in allogeneic transplant: Insights into older patient preferences in an age-friendly multidisciplinary clinic.Org: City of Hope National Medical Center, City of Hope National Comprehensive Cancer Center, City of Hope Comprehensive Cancer Center,